A Bioinformatic Analysis: the Overexpression and Clinical Significance of FCGBP in Ovarian Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Mar 9

PMID 33686968

Citations 20

Authors

Kai Wang

Chenan Guan

Xianwen Shang

Xiang Ying

Shuangshuang Mei

Hanxiao Zhu

Liang Xia

Zeying Chai

Affiliations

Soon will be listed here.

Abstract

Fc fragment of IgG-binding protein (FCGBP) is differentially expressed in various tumors. However, the correlation between FCGBP and immune cell infiltration in ovarian cancer remains unclear. FCGBP expression was analyzed using The Cancer Genome Atlas (TCGA) pan-cancer data, and the ovarian cancer expression profile was analyzed using the Gene Expression Omnibus database. The clinical prognostic value of FCGBP was evaluated using clinical survival data from TCGA. Enrichment analysis of FCGBP was performed using the R package clusterProfiler. Based on known immune cell infiltration scores for samples found in TCGA, we analyzed the association between immune cell infiltration level and FCGBP expression. FCGBP was highly expressed and associated with poorer overall survival (p = 0.00051) and disease-specific survival (p = 0.0012) in ovarian cancer and other tumors. Additionally, high FCGBP expression correlated significantly with immune-related gene sets, including those involved in chemokine signaling pathways and innate and adaptive immunity. Further analysis showed that M2 macrophage infiltration increased and M1 macrophage infiltration decreased in tissues with high FCGBP expression. Our study suggests that FCGBP contributes to M2 macrophage polarization by acting as an oncogene in ovarian cancer. FCGBP may represent a clinically helpful biomarker for predicting overall survival of ovarian cancer patients.

Citing Articles

FCGBP functions as a tumor suppressor gene in head and neck squamous cell carcinoma.

Zeng L, Zeng J, He J, Li Y, Li C, Lin Z Discov Oncol. 2024; 15(1):704.

PMID: 39580769 PMC: 11586324. DOI: 10.1007/s12672-024-01607-8.

Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy.

Su Y, Chen C, Kang J, Kuo H, Yang C, Tian Y Aging (Albany NY). 2024; 16(9):7889-7901.

PMID: 38709264 PMC: 11131975. DOI: 10.18632/aging.205791.

is a potential biomarker for bladder cancer: a Mendelian randomization study.

Tan Z, Chen X, Li H, Huang Y, Fu S, Ding M J Cancer. 2024; 15(6):1624-1641.

PMID: 38370367 PMC: 10869984. DOI: 10.7150/jca.92657.

HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.

Ma S, Wang J, Cui Z, Yang X, Cui X, Li X Sci Rep. 2024; 14(1):3870.

PMID: 38365849 PMC: 10873328. DOI: 10.1038/s41598-024-53854-y.

Investigating the clinical role and prognostic value of genes related to insulin-like growth factor signaling pathway in thyroid cancer.

Liu J, Miao X, Yao J, Wan Z, Yang X, Tian W Aging (Albany NY). 2024; 16(3):2934-2952.

PMID: 38329437 PMC: 10911384. DOI: 10.18632/aging.205524.

References

Xiong L, Wen Y, Miao X, Yang Z . NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res. 2013; 355(2):365-74. PMC: 3921456. DOI: 10.1007/s00441-013-1752-1. View

Bai Y, Yin K, Su T, Ji F, Zhang S . CTHRC1 in Ovarian Cancer Promotes M2-Like Polarization of Tumor-Associated Macrophages via Regulation of the STAT6 Signaling Pathway. Onco Targets Ther. 2020; 13:5743-5753. PMC: 7306458. DOI: 10.2147/OTT.S250520. View

Palaia I, Tomao F, Sassu C, Musacchio L, Benedetti Panici P . Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. Onco Targets Ther. 2020; 13:6109-6129. PMC: 7326187. DOI: 10.2147/OTT.S205950. View

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

Ying X, Wu Q, Wu X, Zhu Q, Wang X, Jiang L . Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016; 7(28):43076-43087. PMC: 5190009. DOI: 10.18632/oncotarget.9246. View

Wang Y, Liu Y, Liu H, Zhang Q, Song H, Tang J . FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients. Oncotarget. 2017; 8(49):86503-86514. PMC: 5689701. DOI: 10.18632/oncotarget.21220. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

Hoffmann W . Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Protection and More: Changing the Paradigm. Int J Mol Sci. 2020; 21(12). PMC: 7350206. DOI: 10.3390/ijms21124535. View

Heuer J, Heuer F, Sturmer R, Harder S, Schluter H, Braga Emidio N . The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions. Int J Mol Sci. 2020; 21(7). PMC: 7177788. DOI: 10.3390/ijms21072508. View

10.

Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View

11.

Rajkumar T, Vijayalakshmi N, Gopal G, Sabitha K, Shirley S, Raja U . Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int. 2010; 10:45. PMC: 3004887. DOI: 10.1186/1475-2867-10-45. View

12.

Vitale I, Manic G, Coussens L, Kroemer G, Galluzzi L . Macrophages and Metabolism in the Tumor Microenvironment. Cell Metab. 2019; 30(1):36-50. DOI: 10.1016/j.cmet.2019.06.001. View

13.

Xu F, Zhan X, Zheng X, Xu H, Li Y, Huang X . A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma. Genomics. 2020; 112(6):4675-4683. DOI: 10.1016/j.ygeno.2020.08.014. View

14.

Gazi M, He M, Cheville J, Young C . Downregulation of IgG Fc binding protein (Fc gammaBP) in prostate cancer. Cancer Biol Ther. 2007; 7(1):70-5. DOI: 10.4161/cbt.7.1.5131. View

15.

Marverti G, Gozzi G, Maretti E, Lauriola A, Severi L, Sacchetti F . A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. Int J Mol Sci. 2020; 21(12). PMC: 7352236. DOI: 10.3390/ijms21124452. View

16.

Liu C, Zhou X, Long Q, Zeng H, Sun Q, Chen Y . Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene. Oncogene. 2020; 40(2):233-245. DOI: 10.1038/s41388-020-01521-7. View

17.

Ma R, Jing C, Zhang Y, Cao H, Liu S, Wang Z . The somatic mutation landscape of Chinese Colorectal Cancer. J Cancer. 2020; 11(5):1038-1046. PMC: 6959081. DOI: 10.7150/jca.37017. View

18.

Qi C, Hong L, Cheng Z, Yin Q . Identification of metastasis-associated genes in colorectal cancer using metaDE and survival analysis. Oncol Lett. 2016; 11(1):568-574. PMC: 4726934. DOI: 10.3892/ol.2015.3956. View

19.

Alvero A, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O . Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology. 2020; 9(1):1758869. PMC: 7302442. DOI: 10.1080/2162402X.2020.1758869. View

20.

Zhang X, Liu L, Tang M, Li H, Guo X, Yang X . The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm. 2020; 46(7):1150-1162. DOI: 10.1080/03639045.2020.1776320. View